Amgevita (adalimumab)

pCPA File Number: 21320
Negotiation Status:
Concluded with an LOI
Indication(s):
Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: